Research on AiGPro Published in International Journal, Identifies Drug Candidates by Analyzing GPCR Interactions

AZothBio, an AI drug development company, has confirmed the commercialization potential of their AI drug development model 'AiGPro' for discovering drug candidates. 

The company recently announced that the research confirming AiGPro's efficiency and accuracy has been published in the international journal 'Journal of Cheminformatics'.

AiGPro is a multitasking AI model that can predict the activities of agonists and antagonists for 231 human cell surface proteins known as G protein-coupled receptors (GPCRs). 

GPCRs are crucial targets for drug development, and many companies are targeting them for new drug development.

In this study, AZothBio confirmed that using AiGPro significantly enhances the efficiency and accuracy of drug discovery. 

By integrating various data sources, AiGPro precisely analyzes the properties and interactions of drug candidates, reducing early-stage uncertainties and providing more reliable predictions.

AZothBio is currently collaborating with several pharmaceutical companies in Japan, leveraging AiGPro and their other developed AI technologies and drugs. 

A company representative stated that the research results prove that AI-based drug development technology is commercially viable and that it will be a significant turning point for expanding into overseas markets.

AZothBio has continuously published AI drug development research results. In 2023, they introduced technologies that enhance the accuracy of drug candidate discovery using protein-ligand interaction prediction AI models and AI-based kinase target prediction technologies, proposing more effective drug development methods.

CEO Jae-Min Shin said, "Based on these research results, we will further commit to AI-driven drug development, seek new opportunities through collaboration with global pharmaceutical companies, and establish our position as a leading company in the bio market through continuous research and development."

출처 : 비즈워치